中国药企发力研发创新药征募志愿者参加研究

2014-08-29 17:14:36来源：可可英语

　　This puts China in a similar position to India, where companies such as Lupin and Ranbaxy havebecome big generic manufacturers but show little sign of developing their own high-valuemedicines. Where the two countries differ, however, is in their approach to the patent systemunderpinning the global pharma industry.

　　这将中国置于类似印度的地位上，印度的鲁宾(Lupin)和兰伯西(Ranbaxy)已成为大型仿制药生产商，但似乎没有自行研发高价值药物的迹象。然而，两国对待支撑全球制药行业的专利制度态度不同。

　　Whereas India is battling with US and European drugmakers over the intellectual propertyrights that allow them to charge premium prices, China has shown less dissent. This, sayanalysts and industry executives, reflects Beijing’s hope that it will eventually become abeneficiary of the patent system when its companies start developing drugs of their own.

　　欧美制药商的产品之所以能开出高价，就是因为有知识产权。印度在知识产权上正在与美国和欧洲制药商展开较量，而中国没有对知识产权制度表现出多少异议。分析师和行业高管表示，从这一点上可以看出，北京方面希望当中国制药商开始自行研发创新药时，中国能成为专利制度的受益者。

　　For several groups, the first step has been to strike partnerships with multinational companies.

　　多家中国制药商的第一步，都是与跨国制药商达成合作。

　　Chi-Med, for example, is developing its colorectal cancer drug, fruquintinib, with Eli Lilly of theUS and is working with AstraZeneca of the UK on another, called volitinib, for renal cell cancer.Beijing-based BeiGene, meanwhile, is developing cancer drugs with Merck of Germany.

　　例如，和黄中国医药正在与美国制药商礼来(Eli Lilly)合作，开发用于治疗结直肠癌的药物——呋喹替尼(Fruquintinib);它还在与英国制药商阿斯利康(AstraZeneca)合作，研发用于治疗肾细胞癌的药物——沃利替尼(Volitinib)。与此同时，总部位于北京的制药商百济神州(BeiGene)正在与德国制药商默克(Merck)合作开发癌症药物。

　　George Baeder, an adviser to local and multinational pharma companies, predicts more than adozen Chinese-originated products will enter the clinic in the next three years. “Then theindustry will have to recognise China’s role as a drug innovator,” he said.

　　为中国本地和跨国制药企业提供服务的咨询顾问乔治•贝德(George Baeder)预测，未来3年内，将有逾12种中国发明的新药投入临床使用。他说：“届时，制药业将不得不承认中国在创新药研发中的地位。”

　　China’s potential to become a force in pharmaceutical R&D has been evident since the1960s when Mao Zedong ordered the Chinese army to find a treatment for malaria, which wasravaging North Vietnamese soldiers in their jungle battles with US-backed South Vietnam.

　　中国在医药研发方面的潜力在上世纪60年代就表现出来了，当时，北越在跟美国支持的南越打丛林战，而疟疾在北越士兵中肆虐，于是毛泽东命令中国军队寻找治疗疟疾的药方。

　　This programme discovered artemisinin, which remains one of the most important weaponsagainst malaria. It was derived from the sweet wormwood plant – a herb used in Chinesemedicine for centuries – highlighting the potential to marry the country’s traditional medicalpractices with modern science.

　　经过努力，中国人发现了青蒿素——至今仍然是对付疟疾最重要的武器之一。青蒿素是从黄花蒿茎叶中提取的，这种植物几个世纪以来一直是一味中药，显示出中国传统中医在与现代科技结合方面存在巨大潜力。

　　However, it was not until the 1990s, when an artemisinin-based drug was commercialised byNovartis of Switzerland, that this Chinese innovation was made available to the wider world.Beijing wants to make sure future discoveries reach the global market more quickly – and withdomestic companies taking them all the way.

　　然而，直到上世纪90年代、瑞士诺华将一种基于青蒿素的药物商业化以后，这项中国的创新才得以造福世界。北京方面希望确保未来的发明能更快推向全球市场，而且由中国本土企业全程研发和制造。

本文关键字: 中国药企发力研发创新药